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We routinely face decisions that require weighing the relative costs and benefits associated with different rewards in order to select better courses of action, and these functions are disrupted in psychiatric disorders such as schizophrenia. Nodes within the mesocorticolimbic dopamine system interact in situations of reward uncertainty to guide risk/reward decisions, and preclinical studies from our group has revealed that these types of decisions are mediated in part by dopamine activity within the medial prefrontal cortex. In these studies, rats are trained to choose between levers that deliver small/certain or large/uncertain rewards-the odds of which change systematically across 4 blocks of discrete-choice trials (100%-12.5%). This presentation will describe neurochemical, behavioral pharmacological and disconnection studies that clarify some of the mechanisms through which mesocortical dopamine regulates different competent processes underlying decisions involving reward uncertainty. In vivo microdialysis studies reveal that dynamic fluctuations in tonic prefrontal dopamine transmission appear to encode distinct types of information related to changes in reward availability, serving as a "reward running rate meter". These studies are complemented by behavioral pharmacological experiments targeting dopamine D1 and D2 receptors in the prefrontal cortex, demonstrating that these receptors makes dissociable, yet complementary, contributions to risk/reward judgments. Specifically, D1 receptor activity appears to promote exploitation of current favorable circumstances, whereas activation of D2 receptors within the PFC promotes exploration of more profitable options when conditions change. Furthermore, these dissociable actions of D1 or D2 receptor subtypes exert their differential effects via distinct subcortical output pathways. Selectively disrupting D1 modulation of prefrontal projections to the ventral striatum (but not prefrontal-amygdala projections) reduced preference for large/risky rewards, which was driven primarily by a reduction in reward sensitivity and an increased sensitivity to non-rewarded actions. In contrast, disrupting D2 modulation of prefrontal projections to the basolateral amygdala impaired the ability to update decision biases in response to changes in reward probabilities. These findings provide novel insight into the dopaminergic microcircuits within the prefrontal cortex that facilitate reward seeking and efficient decision making and in turn may inform how perturbations in these signals may related to impaired reward processing and decision making observed in psychiatric disorders. Title: Translational neuroscience perspectives on stress and fear Abstract Anxiety and depressive disorders frequently begin during adolescence or early childhood and are among the most common psychiatric illnesses. Many children with these stress-related disorders are either not properly diagnosed or are ineffectively treated resulting in long term suffering, altered psychosocial development, disability, and increased risk for adult psychopathology. To improve the treatment and long term outcomes of these children, it is critical to understand the factors that increase the risk for developing these disorders. Our research takes a translational, developmental approach combining imaging, mechanistic and molecular studies in young rhesus monkeys with neuroimaging studies in preadolescent children with anxiety disorders. Early childhood extreme behavioral inhibition, or anxious temperament (AT) is a prominent risk factor for the later emergence of anxiety and depressive disorders and can be modeled in young rhesus monkeys. We first developed and validated a model of AT in young monkeys and then in a large cohort used FDG-PET imaging to define the neural circuit (PFC regions, extended amygdala, anterior hippocampus, periqueductal gray) that underlies extreme AT. Selective lesion studies combined with imaging identified the central nucleus of the amygdala (Ce) as causally mediating AT, with the orbitofrontal cortex likely serving a role in regulating the extended amygdala. Our large extended multigenerational pedigree (n=592) allowed us to perform heritability studies establishing that AT is approximately 35% heritable. Importantly, we also performed voxelwise heritability analyses on brain structure and function, and with a genetic correlation approach, found regions in which metabolism likely mediates the intergenerational transfer of AT. By examining mRNA expression in the Ce, we identified alterations in gene transcription that support a neurodevelopmental model that posits that reduced neuroplasticity within the core nodes of the neural circuit underlying AT are responsible for maintaining the childhood risk to develop anxiety and depression. Finally, to test the role of these newly identified gene alterations, we developed methods in the primate to manipulate gene expression by site specifically delivering viral vectors containing relevant constructs. Taken together, these studies have the potential to facilitate the development of new, neurally informed childhood biomarkers and novel early interventions. Abstract Posttraumatic stress disorder is characterized by the failure of the acute fear response to diminish after exposure to a lifethreatening traumatic event. Risk factors for PTSD include sex (female), education (less), and familial and genetic factors, as well as factors pertaining to the type and severity of trauma(s) experienced by the individual over time (including childhood maltreatment). The increased risk for PTSD when a traumatic event includes physical injury, particularly traumatic brain injury (TBI), is well recognized, and points to a role for certain brain circuits and systems in the pathogenesis of PTSD. In this presentation, Dr. Stein will review recent findings on brain imaging and genetic factors pertinent to the understanding of PTSD and related disorders. He will also review the evidence base for PTSD treatments. 
S12: Translational Neuroscience

Abstract
The limitations of standard antidepressant treatments are well known, they work for too few patients and their beneficial effects emerge too slowly. APPROACH: The purpose of this presentation is to briefly describe the context leading to the discovery of the antidepressant effects of ketamine in humans, to characterize our current understanding of the profile of ketamine's efficacy and ways that it is entering routine clinical treatment, to consider the management of risks associated with ketamine treatment, and to consider emerging alternatives to ketamine. Emerging studies also point to ketamine effectiveness in PTSD. CONCLUSIONS: The rapidity (onset within 24 hours) and magnitude (50%-75% clinical response rate, even in treatment-resistant depression populations) of the efficacy of ketamine suggest that it could be a new and important role in the treatment of mood disorders where clinical response is needed urgently or where there has been inadequate response to other treatments. Disclosure: Dr. Krystal is a co-proponent of a use patent related to the intranasal administration of ketamine for the treatment of depression that has been licensed by Johnson and Johnson.
